Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
NCT03097107 · Zydus Therapeutics Inc. · PHASE2 · suspended · last registry update 2023-02-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Management decision to suspend the study due to recruitment issues” | – | Registry record, Zydus Therapeutics Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-22Results posted on the registry: Kowa Research Institute, Inc., K-877-ER (Dose A) + K-877-ER (Dose B) (NCT04447820)
- 2023-12-18Phase 3 first posted: Han Ying, Fenofibrate + Placebo (NCT06174402)
- 2023-11-09Phase 3 first posted: Shengjing Hospital, Chiglitazar + Metformin (NCT06125587)
- 2023-09-28Results posted on the registry: University of California, Irvine, Fenofibrate + Placebo (NCT03515213)
- 2023-08-30Phase 3 first posted: Ipsen, Elafibranor (NCT06016842)
- 2023-06-28Phase 3 first posted: Kowa Company, Ltd., K-877 0.2 mg/day (once daily) + K-877 0.4 mg/day (once daily) (NCT05923281)
- 2023-06-23Also stopped (withdrawn): St. Louis University, Pioglitazone 30 mg + placebo tablet (NCT04995978)
- 2023-05-15Also stopped (withdrawn): St. Louis University, Pioglitazone 30 Mg Oral Tablet + Pioglitazone placebo tablet (NCT04658849)
- 2023-05-06Results posted on the registry: Sanofi, Alirocumab SAR236553 (REGN727) + Rosuvastatin (NCT03510884)
- 2023-03-03Phase 3 first posted: Tanta University, Mesalamine + Fenofibrate 160mg (NCT05753267)
- 2023-03-02Phase 3 first posted: Xijing Hospital of Digestive Diseases, Placebo Combined With Ursodeoxycholic Acid + Fenofibrate Combined With Ursodeoxycholic Acid (NCT05751967)
- 2023-03-01Phase 3 first posted: Xijing Hospital of Digestive Diseases, Fenofibrate 200mg + Placebo (NCT05749822)
- 2023-02-27Results posted on the registry: University of Pennsylvania, a drug against PPARA (NCT04517396)
- 2023-02-24Results posted on the registry: University of Guadalajara, Berberine + Bezafibrate (NCT02548832)
- 2022-11-30Results posted on the registry: Kowa Research Institute, Inc., K-877 + Fenofibrate (NCT03001817)
- 2022-11-03Results posted on the registry: Genfit, GFT505 80mg + GFT505 120mg (NCT01694849)
- 2022-10-28Results posted on the registry: Kowa Research Institute, Inc., K-877 + Fenofibrate (NCT03011450)
- 2022-04-25Results posted on the registry: Amarin Pharma Inc., AMR101 (ethyl icosapentate) - 4 g/day + AMR101 (ethyl icosapentate) - 2 g/day (NCT01047501)
- 2022-04-25Results posted on the registry: Amarin Pharma Inc., AMR101 (ethyl icosapentate) - 4 g/day + AMR101 (ethyl icosapentate) - 2 g/day (NCT01047683)
- 2022-04-14Results posted on the registry: Amarin Pharma Inc., AMR101 + Placebo (NCT01492361)
- 2022-03-23Results posted on the registry: Genfit, Elafibranor + Placebo (NCT02704403)
- 2022-03-23Also stopped (terminated): Genfit, Elafibranor + Placebo (NCT02704403)
- 2022-02-08Results posted on the registry: Medical University of South Carolina, Fenofibrate (NCT03829514)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision